한글목차

급성호흡곤란증후군 치료 세계 시장, 2030년까지 43억 달러 규모에 달할 전망

2023년 31억 달러로 추정되는 급성호흡곤란증후군 치료제 세계 시장은 2023-2030년 동안 연평균 4.9%의 CAGR로 성장하여 2030년에는 43억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 경구 투여 부문은 CAGR 4.8%를 기록하여 분석 기간 종료 시점에 21억 달러에 도달할 것으로 예상됩니다. 주사제 부문은 분석 기간 동안 CAGR 6.0%의 성장률을 기록할 것으로 추정됩니다.

미국 시장 8억 3,400만 달러로 추정, 중국은 CAGR 8.0%로 성장 전망

미국의 급성호흡곤란증후군 치료 시장은 2023년 8억 3,400만 달러에 달할 것으로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 8억 8,000만 달러의 시장 규모에 도달할 것으로 예상되며, 2023-2030년 분석 기간 동안 8.0%의 CAGR을 기록할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 1.9%와 5.0%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 2.9%의 CAGR로 성장할 것으로 예상됩니다.

세계 급성호흡곤란증후군 치료 시장 - 주요 동향 및 촉진요인 요약

급성호흡곤란증후군(ARDS)은 폐의 광범위한 염증의 급속한 발병을 특징으로 하는 생명을 위협하는 심각한 질환으로, 폐렴, 패혈증, 외상, 유해물질 흡입 등 다양한 기저질환에서 발생할 수 있으며, ARDS의 치료는 주로 폐기능을 유지하고 근본적인 원인을 해결하는 데 중점을 둡니다. 에 중점을 둡니다. 충분한 산소화를 보장하기 위해 기계적 환기가 종종 필요하며, 추가 폐 손상을 최소화하기 위해 저타이드량 환기와 같은 전략이 채택됩니다. 환자를 엎드린 자세로 누워있는 복부 자세도 혈류를 재분배하고 폐의 압박을 줄여 산소화를 개선할 수 있습니다. 체외막산소요법(ECMO)과 같은 보조 요법은 기존의 기계적 환기가 충분하지 않은 중증 환자에게 사용됩니다.

기계적 보조 외에도 약리학적 개입은 ARDS 관리에 중요한 역할을 합니다. 부신피질 스테로이드는 일반적으로 염증을 억제하고 결과를 개선하기 위해 투여됩니다. 환기를 촉진하고 산소화를 개선하기 위해 신경근 차단제와 같은 다른 약물을 사용하기도 합니다. 수액 관리는 매우 중요하며, 수액 과다 및 폐부종 악화를 방지하기 위해 보존적 접근법이 종종 채택됩니다. 새로운 치료법과 현재 진행 중인 연구들은 손상된 폐 조직을 복구하고 재생하기 위한 줄기세포 치료와 항염증 효과가 있는 스타틴의 사용과 같은 치료 가능성을 모색하고 있으며, ARDS 치료는 복잡하기 때문에 환자의 결과를 최적화하기 위해 폐 전문의, 중환자의학과 전문의, 호흡기 치료사가 협력하는 다학제적 접근이 필요합니다. 협력하는 다학제적 접근이 필요합니다.

ARDS 치료 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 의료 기술의 발전으로 진단 능력이 크게 향상되어 ARDS 관리에 필수적인 조기 발견과 개입이 가능해졌습니다. 중증 감염 및 만성 질환 등 ARDS를 유발할 수 있는 질환의 유병률이 증가함에 따라 효과적인 치료 옵션에 대한 수요가 증가하고 있습니다. 또한, COVID-19 팬데믹은 첨단 호흡기 지원의 중요성을 부각시키며 ARDS 치료에 대한 혁신과 투자를 가속화하고 있습니다. 또한, 환자 개개인의 프로파일에 맞게 치료법을 조정하여 효과와 결과를 개선하는 개인 맞춤형 의료에 대한 중요성이 강조되고 있습니다. 정부 및 민간 부문의 중환자 치료 연구개발에 대한 자금 지원은 ARDS에 대한 새로운 치료 옵션의 개발을 촉진하며 시장을 더욱 촉진하고 있습니다.

조사 대상 기업 예시(총 86개사)

• Advocate Health Care, Inc.
• Aqualung Therapeutics
• Athersys, Inc.
• BioAegis（R）Therapeutics Inc.
• Dragerwerk AG & Co. KGaA
• Eurosets S.R.L.
• Fisher & Paykel Healthcare Corporation Ltd.
• Gen1E Lifesciences
• Getinge AB(Getinge Group)
• HEALIOS K.K.
• Medtronic UK
• North Memorial Health
• Roche Diagnostics International AG
• Savara, Inc.
• Veru, Inc.

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 성장 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Acute Respiratory Distress Syndrome Treatment Market to Reach US$4.3 Billion by 2030

The global market for Acute Respiratory Distress Syndrome Treatment estimated at US$3.1 Billion in the year 2023, is expected to reach US$4.3 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Injection Administration segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$834.0 Million While China is Forecast to Grow at 8.0% CAGR

The Acute Respiratory Distress Syndrome Treatment market in the U.S. is estimated at US$834.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$880.0 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Acute Respiratory Distress Syndrome Treatment Market - Key Trends and Drivers Summarized

Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening condition characterized by rapid onset of widespread inflammation in the lungs. ARDS can result from various underlying conditions such as pneumonia, sepsis, trauma, or inhalation of harmful substances. The treatment of ARDS primarily focuses on supporting lung function and addressing the underlying cause. Mechanical ventilation is often necessary to ensure adequate oxygenation, and strategies such as low tidal volume ventilation are employed to minimize further lung injury. Prone positioning, where patients are laid on their stomachs, can also improve oxygenation by redistributing blood flow and reducing lung compression. Adjunctive therapies like extracorporeal membrane oxygenation (ECMO) may be used in severe cases where conventional mechanical ventilation is insufficient.

In addition to mechanical support, pharmacological interventions play a crucial role in ARDS management. Corticosteroids are commonly administered to reduce inflammation and improve outcomes. Other medications, such as neuromuscular blockers, may be used to facilitate ventilation and improve oxygenation. Fluid management is critical, with a conservative approach often adopted to prevent fluid overload and worsening lung edema. Emerging treatments and ongoing research are exploring the potential of therapies such as stem cell treatment, which aims to repair and regenerate damaged lung tissue, and the use of statins, which have anti-inflammatory properties. The complexity of ARDS treatment necessitates a multidisciplinary approach, involving pulmonologists, critical care specialists, and respiratory therapists working together to optimize patient outcomes.

The growth in the ARDS treatment market is driven by several factors. Advances in medical technology have significantly improved diagnostic capabilities, allowing for earlier detection and intervention, which is crucial for ARDS management. The rising prevalence of conditions that can lead to ARDS, such as severe infections and chronic illnesses, is increasing the demand for effective treatment options. Additionally, the COVID-19 pandemic has highlighted the critical need for advanced respiratory support, leading to accelerated innovation and investment in ARDS treatments. There is also a growing emphasis on personalized medicine, where treatments are tailored to individual patient profiles, improving efficacy and outcomes. Government and private sector funding for research and development in critical care medicine further propels the market, fostering the development of new and improved therapeutic options for ARDS.

Select Competitors (Total 86 Featured) -

• Advocate Health Care, Inc.
• Aqualung Therapeutics
• Athersys, Inc.
• BioAegis(R) Therapeutics Inc.
• Dragerwerk AG & Co. KGaA
• Eurosets S.R.L.
• Fisher & Paykel Healthcare Corporation Ltd.
• Gen1E Lifesciences
• Getinge AB (Getinge Group)
• HEALIOS K.K.
• Medtronic UK
• North Memorial Health
• Roche Diagnostics International AG
• Savara, Inc.
• Veru, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Acute Respiratory Distress Syndrome Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of ARDS Due to COVID-19 and Other Respiratory Infections
  • Advances in Critical Care and Respiratory Therapies
  • Increasing Investment in ARDS Research
  • Development of Novel Therapeutics and Interventions
  • Expansion of Clinical Trials for ARDS Treatments
  • Growing Demand for Mechanical Ventilation and ECMO
  • Integration of Personalized Medicine in ARDS Treatment
  • Technological Innovations in Respiratory Support Devices
  • Rising Awareness and Diagnosis Rates
  • Patient Access and Reimbursement Issues
  • Increasing Focus on Early Intervention and Prevention
  • Growth of Telemedicine and Remote Monitoring
  • Expansion of Healthcare Infrastructure and ICU Capacity
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Acute Respiratory Distress Syndrome Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Acute Respiratory Distress Syndrome Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Injection Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Injection Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Injection Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Inhalation Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Inhalation Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Inhalation Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• JAPAN
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• CHINA
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 41: China Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: China 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• EUROPE
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Acute Respiratory Distress Syndrome Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• FRANCE
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: France 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 59: France Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• GERMANY
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 77: UK Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Spain 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Russia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of Europe 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Asia-Pacific 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 107: Australia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Australia Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Australia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Australia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• INDIA
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 113: India Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: India Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: India 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 116: India Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: India 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 119: South Korea Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: South Korea Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: South Korea 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: South Korea 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Rest of Asia-Pacific Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 131: Latin America Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 132: Latin America Historic Review for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Latin America 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 140: Argentina Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Argentina Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Argentina 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Argentina 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 146: Brazil Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Brazil Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Brazil 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Brazil 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 152: Mexico Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Mexico Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Mexico 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Mexico 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Rest of Latin America Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Rest of Latin America 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Rest of Latin America 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 164: Middle East Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 165: Middle East Historic Review for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Middle East 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 173: Iran Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Iran Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Iran 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Iran 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 179: Israel Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Israel Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Israel 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Israel 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Saudi Arabia Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Saudi Arabia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Saudi Arabia 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 191: UAE Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: UAE Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: UAE 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: UAE 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Rest of Middle East Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Rest of Middle East 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Rest of Middle East 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• AFRICA
  • Acute Respiratory Distress Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 203: Africa Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Africa Historic Review for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Oral Administration, Injection Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Africa 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration, Injection Administration and Inhalation Administration for the Years 2014, 2024 & 2030
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Africa 16-Year Perspective for Acute Respiratory Distress Syndrome Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION